MNPR (Monopar Therapeutics) Institutional Ownership: 97.54% (As of Jul. 11, 2026)


MNPR Monopar Therapeutics Inc MNPR
35 GF Score
Price $106.60
! 3 Warning Signs
View Full Analysis

What is Monopar Therapeutics Institutional Ownership?

Monopar Therapeutics MNPR +2.30% 35 Institutional Ownership is 97.54% as of Jul. 11, 2026. GuruFocus rates MNPR with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Monopar Therapeutics's institutional ownership is 97.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Monopar Therapeutics's Insider Ownership is 7.30%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Monopar Therapeutics's Float Percentage Of Total Shares Outstanding is 68.26%.

Monopar Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Monopar Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Monopar Therapeutics Institutional Ownership Chart

Monopar Therapeutics Historical Data

The historical data trend for Monopar Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 10.43 10.87 12.84 17.19 17.83 20.10 19.37 18.98 18.86 19.11
MNPR
35GF Score
Monopar Therapeutics Inc MNPR
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Monopar Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 97.54% mean?
Monopar Therapeutics (MNPR) has a Institutional Ownership of 97.54% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Monopar Therapeutics and its competitors.
Is Monopar Therapeutics' Institutional Ownership too high?
Monopar Therapeutics' current Institutional Ownership is 97.54%. Overall, Monopar Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Monopar Therapeutics' Institutional Ownership compare to MDXG and FTH?
Monopar Therapeutics' Institutional Ownership of 97.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Monopar Therapeutics and its competitors. Monopar Therapeutics's current Institutional Ownership is 97.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Monopar Therapeutics stock overvalued right now?
Monopar Therapeutics (MNPR) has a current Institutional Ownership of 97.54%. The current Institutional Ownership is 97.54%. Monopar Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Monopar Therapeutics (MNPR), the current Institutional Ownership is 97.54% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Monopar Therapeutics Business Description

Other Exchanges 1IY0:Germany
Address 1000 Skokie Boulevard, Suite 350, Wilmette, IL, USA, 60091
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
35GF Score

Get the complete analysis for MNPR

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$106.60
Price